Interesting Correlation Between the Circulating Pentraxin 3 and Cardiac Rehabilitation Program Outcomes in Coronary Artery Bypass Grafting Patients.

Habib Haybar, Babak Payami, Isa Khaheshi, Yasaman Ghotbi, Seyed Mahmoud Latifi, Ahmadreza Assareh
Author Information
  1. Habib Haybar: Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  2. Babak Payami: Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  3. Isa Khaheshi: Cardiovascular Research Center, Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  4. Yasaman Ghotbi: Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  5. Seyed Mahmoud Latifi: Health Research Institute, Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  6. Ahmadreza Assareh: Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Abstract

BACKGROUND: Pentraxin 3 (PTX3) is an inflammatory mediator, reaches to the high levels after ischemic heart diseases (IHD) and could be a helpful tool to predict cardiac rehabilitation (CR) outcomes. The aim of this study was to investigate the possibility of the circulating levels of PTX3 in prediction of CR outcomes in patients with IHD who had undergone coronary artery bypass grafting (CABG).
METHODS: One hundred patients who had undergone CABG were included in this study. The CR plan was started 6 weeks after CABG and then PTX3 level, high-sensitivity C-reactive protein (hs-CRP), ejection fraction (EF) and metabolic equivalent (MET) were assessed before and after the CR program. Finally, all gathered data were analyzed using SPSS version 22.
RESULTS: After a 3-month course of CR program, EF, MET, PTX3 and hs-CRP values changed. Statistically significant changes were observed in EF, MET and PTX3 values (P < 0.05) after the CR program and no statistically significant changes were seen in hs-CRP value (P = 0.546) at the end of CR program. Correlations between EF levels and MET with pre-PTX3 levels were also assessed and most changes were observed in the group with pre-PTX3 level more than 0.40 ng/dL.
CONCLUSION: Our study showed that a regular sufficient CR program based on exercises in IHD patients after CABG increases EF and MET levels, particularly in those patients with pre-PTX3 levels more than 0.40 ng/dL.

Keywords

References

  1. Clin J Am Soc Nephrol. 2007 Sep;2(5):889-97 [PMID: 17702732]
  2. Eur J Appl Physiol. 2010 Nov;110(5):905-13 [PMID: 20640440]
  3. J Cardiopulm Rehabil Prev. 2012 Jan-Feb;32(1):17-24 [PMID: 22193930]
  4. Am Heart J. 2012 Feb;163(2):274-9 [PMID: 22305847]
  5. Vascul Pharmacol. 2006 Nov;45(5):326-30 [PMID: 17023219]
  6. Circulation. 2009 Aug 25;120(8):699-708 [PMID: 19667236]
  7. Ann Rehabil Med. 2011 Aug;35(4):535-40 [PMID: 22506170]
  8. PLoS One. 2012;7(2):e31474 [PMID: 22319633]
  9. Circulation. 2000 Aug 8;102(6):636-41 [PMID: 10931803]
  10. Appl Physiol Nutr Metab. 2012 Oct;37(5):907-11 [PMID: 22784030]
  11. Trends Cardiovasc Med. 2010 Feb;20(2):35-40 [PMID: 20656213]
  12. Circulation. 2008 Feb 26;117(8):1055-64 [PMID: 18268142]
  13. BMC Cardiovasc Disord. 2007 Oct 30;7:32 [PMID: 17971195]
  14. Rehabil Nurs. 2015 Sep-Oct;40(5):305-9 [PMID: 24842623]
  15. Am J Med. 2004 May 15;116(10):682-92 [PMID: 15121495]
  16. Am J Public Health. 1990 Nov;80(11):1363-7 [PMID: 2240306]
  17. Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):161-7 [PMID: 17095712]
  18. Circulation. 2003 Aug 5;108(5):554-9 [PMID: 12860904]
  19. ISRN Inflamm. 2013 Sep 14;2013:379040 [PMID: 24167754]
  20. J Investig Med. 2013 Feb;61(2):278-85 [PMID: 23237880]
  21. Nat Rev Cardiol. 2013 Feb;10(2):59 [PMID: 23296068]
  22. Eur J Prev Cardiol. 2012 Dec;19(6):1393-400 [PMID: 21914683]
  23. Clin J Am Soc Nephrol. 2011 Apr;6(4):785-92 [PMID: 21330486]
  24. Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):e10-4 [PMID: 12006411]
  25. Nephrol Dial Transplant. 2011 Jun;26(6):1903-8 [PMID: 21079193]
  26. J Am Coll Cardiol. 2004 Mar 17;43(6):1056-61 [PMID: 15028366]
  27. J Pathol. 2008 May;215(1):48-55 [PMID: 18220316]
  28. J Immunol. 2008 Dec 15;181(12):8433-40 [PMID: 19050261]
  29. Curr Pharm Des. 2011;17(1):38-46 [PMID: 21226667]
  30. Nature. 2002 Nov 14;420(6912):182-6 [PMID: 12432394]
  31. Heart. 2013 May;99(9):640-8 [PMID: 23468517]
  32. Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):594-9 [PMID: 19164811]
  33. Clin Rehabil. 2008 Apr;22(4):306-18 [PMID: 18390974]
  34. Circulation. 2004 Oct 19;110(16):2349-54 [PMID: 15477419]
  35. Korean Circ J. 2014 Jul;44(4):220-6 [PMID: 25089133]

Word Cloud

Created with Highcharts 10.0.0CRlevelsPTX3patientsCABGEFMETprogram0Pentraxin3IHDstudyhs-CRPchangespre-PTX3rehabilitationoutcomesundergonelevelfractionequivalentassessedvaluessignificantobservedP40ng/dLCardiacBACKGROUND:inflammatorymediatorreacheshighischemicheartdiseaseshelpfultoolpredictcardiacaiminvestigatepossibilitycirculatingpredictioncoronaryarterybypassgraftingMETHODS:Onehundredincludedplanstarted6weekshigh-sensitivityC-reactiveproteinejectionmetabolicFinallygathereddataanalyzedusingSPSSversion22RESULTS:3-monthcoursechangedStatistically<05statisticallyseenvalue=546endCorrelationsalsogroupCONCLUSION:showedregularsufficientbasedexercisesincreasesparticularlyInterestingCorrelationCirculatingRehabilitationProgramOutcomesCoronaryArteryBypassGraftingPatientsEjectionMetabolictest

Similar Articles

Cited By